Skip to main content

Table 2 Summary of subgroup analysis for the safety of voriconazole and other antifungals

From: Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections

Outcome Subgroup Variables No. of studies No. of patients OR (95% CI) I 2% P
VRC counterpart
Tolerability Antifungals FLU 2 5/218 2/197 0.86 (0.02, 38.38) 73 0.94
AMB 1 19/415 23/422 0.83 (0.45, 1.55) NA 0.56
ITRA 3 91/330 70/311 1.42 (0.98, 2.06) 0 0.06
MCF 4 52/184 24/183 3.19 [1.77, 5.76] 0 0.0001
ISA 1 35/259 21/257 1.76 (0.99, 3.11) NA 0.05
Therapeutic purpose definitive 6 69/830 31/672 1.87 [1.20, 2.92] 0 0.005
empirical 3 63/511 44/521 2.10 (0.72, 6.15) 80 0.18
prophylaxis 3 87/313 71/299 1.35 (0.67, 2.69) 34 0.40
Duration <14d 3 63/511 44/521 2.10 (0.72, 6.15) 80 0.18
≥14d 9 156/1143 102/971 1.54 [1.16, 2.05] 0 0.003
Neurotoxicity Antifungals FLU 1 10/200 13/191 0.72 [0.31, 1.69] NA 0.45
AMB 2 20/609 3/607 6.87 [2.04, 23.16] 21 0.002
ITRA 3 29/330 15/311 1.62 [0.84, 3.14] 52 0.15
MCF 3 13/138 0/134 10.28 [1.91, 55.44] 0 0.007
ISA 1 175/259 165/257 1.16 [0.81, 1.67] NA 0.42
Therapeutic purpose definitive 6 208/776 182/735 1.27 [0.93, 1.73] 26 0.13
empirical 2 22/465 2/472 9.57 [2.57, 35.60] 0 0.0008
prophylaxis 2 17/295 12/293 1.40 [0.66, 2.97] 69 0.39
Duration ≥14d 8 225/1071 194/1028 1.29 [0.97, 1.72] 29 0.08
<14d 2 22/465 2/472 9.57 [2.57, 35.60] 0 0.0008
Visual toxicity Antifungals FLU 3 77/523 35/492 2.11 [1.38, 3.24] 66 0.0006
AMB 3 97/624 4/625 28.83 [10.84, 76.64] 75 <0.00001
ITRA 2 37/259 0/259 46.57 [5.89, 368.06] 0 0.0003
MCF 3 31/138 0/134 26.63 [5.15, 137.62] 0 <0.0001
ISA 1 69/259 39/257 2.03 [1.31, 3.15] NA 0.002
Therapeutic purpose definitive 8 175/1039 57/875 3.33 [2.41, 4.59] 49 <0.00001
empirical 2 103/465 2/472 53.85 [15.23, 190.37] 0 <0.00001
prophylaxis 3 44/547 20/542 1.93 [1.11, 3.36] 68 0.02
Duration <14d 11 219/1586 77/1417 2.92 [2.21, 3.85] 57 <0.00001
≥14d 2 103/465 2/472 53.85 [15.23, 190.37] 0 <0.00001
Hepatotoxicity Antifungals FLU 2 14/218 7/197 1.76 (0.71, 4.36) 0 0.22
AMB 3 128/624 131/625 0.99 (0.74, 1.32) 0 0.95
ITRA 4 46/363 21/344 2.19 (1.27, 3.76) 0 0.005
MCF 3 35/138 15/134 2.78 (1.38, 5.60) 4 0.004
ISA 1 42/259 23/257 1.97 (1.15, 3.38) NA 0.01
Therapeutic purpose definitive 8 156/1039 76/875 1.79 (1.18, 2.71) 29 0.006
empirical 2 128/465 132/472 0.98 (0.73, 1.30) 0 0.88
prophylaxis 4 44/346 21/332 2.11 (1.22, 3.63)0 0 0.07
Duration <14d 2 128/465 132/472 0.98 (0.73, 1.30) 0 0.88
≥14d 11 194/1352 93/1174 1.82 (1.31, 2.54) 19 0.0003
Nephrotoxicity Antifungals FLU 0 NA NA NA NA NA
AMB 3 45/624 110/625 0.15 (0.03, 0.84) 78 0.03
ITRA 1 1/71 0/52 2.23 (0.09, 55.94) NA 0.62
MCF 3 8/138 10/134 0.70 (0.25, 1.94) 0 0.49
ISA 1 58/259 55/257 1.06 (0.70, 1.61) NA 0.79
Therapeutic purpose definitive 6 89/804 122/666 0.36 (0.14, 0.91) 78 0.03
empirical 2 44/465 81/472 0.50 (0.34, 0.74) 0 0.0006
prophylaxis 1 1/71 0/52 2.23 (0.09, 55.94) NA 0.62
Duration <14d 2 44/465 81/472 0.50 (0.34, 0.74) 0 0.0006
≥14d 7 90/875 122/718 0.41 (0.17, 0.98) 74 0.05
  1. NA not applicable